Trimetazidine Hydrochloride in Amyotrophic Lateral Sclerosis: NL-OMON52162 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Completed
Recruitment status
not reported
Planned enrollment
2023-05-22
Primary-completion proxy
Executive view
NL-OMON52162 evaluates Trimetazidine Hydrochloride in Amyotrophic Lateral Sclerosis. The disclosed sponsor is The University of Queensland, the design is Interventional, and the geographic footprint is Netherlands. The first listed primary endpoint is not reported, assessed over an unreported time frame.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NL-OMON52162 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Amyotrophic Lateral Sclerosis landscape. Drug & Asset MCP drug_fetch was queried for Trimetazidine Hydrochloride, while Company & Deal Intelligence MCP organization_fetch was queried for The University of Queensland.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NL-OMON52162 | Trimetazidine Hydrochloride | Phase 2 / Completed | The University of Queensland | Netherlands | 2023-05-22 | |
| NCT05797701 | Oditrasertib | Phase 1 / Completed | Sanofi | United States | Part 1: Maximum plasma concentration observed (Cmax) In both Period 1 and Period 2: From Day 1 to Day 3 | 2021-09-06 |
| NCT05797753 | Itraconazole | Phase 1 / Completed | Sanofi | United States | Part A: SAR443820: Area under the plasma concentration from time zero to the last concentration above the limit of quan… Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10 | 2022-07-01 |
| NCT05795907 | Oditrasertib | Phase 1 / Completed | Sanofi | United States | Parts 1a and 1b: Number of participants with adverse events Day1 up to Day 7 (end of study visit) | 2021-07-20 |
| NCT05753852 | Tauroursodeoxycholate sodium | Phase 3 / Unknown status | Humanitas Mirasole SpA | Netherlands, Belgium, Ireland, United Kingdom, Italy, France, Germany | Long-term safety and tolerability of TUDCA during the open-label phase 18 months | 2025-03-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NL-OMON52162 is a Phase 2, completed study with not reported planned participants. Allocation is not reported, masking is not reported, and the intervention model is not reported.
The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: The primary endpoints are safety and tolerability of trimetazidine, and the change from baseline of oxidative stress markers. The safety and tolerability of trimetazidine will be determined by examining the toxicities and AEs that are attributable to treatment. The safety parameters will include an assessment of clinical signs and symptoms from the history and physical exam, vital signs, AEs, and laboratory findings (e.g. liver and kidney function). The change from baseline of oxidative stress markers will be determined by quantitative analyses of plasma and/or serum samples by liquid chromatography- mass spectr….
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Amyotrophic Lateral Sclerosis. These records do not establish direct evidence for NL-OMON52162 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Trimetazidine Hydrochloride is indexed as Small molecule drug with ACAA2 biology and a global stage of Approved. The asset profile lists Les Laboratoires Servier SAS as an originator or developer.
The University of Queensland is indexed in an unreported country with the website http://www.uq.edu.au.libproxy1.nus.edu.sg A public university located Brisbane, Australia The record lists 29 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Trimetazidine Hydrochloride is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NL-OMON52162
Protocol source: https://onderzoekmetmensen.nl/en/trial/52162
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.
Trimetazidine Hydrochloride in Amyotrophic Lateral Sclerosis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and 2023-05-22 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
